To fill this need, we developed a simplified molecular subtype classification based on the mutational status of only EGFR, KRAS, and TP53 to facilitate categorization of patients’ lung adenocarcinomas into molecular subtypes with relevant prognostic information. This evidence concerns the gene KRAS and lung adenocarcinoma.